The Significance To Detect Serum CaN And PTHrP In Lung Cancer With Bone Metastases

Lung carcinoma is most common among cancers in worldwide. Incidence andmortality of lung carcinoma rises along with the rapid development of industry on worldscaleas the first cause of death from cancer overall and the ratio is17.8%.Bone is one of the most common site of lung cancer metastasis, bone metastases areoften associated with skeletal-related events(SRE) including pain, spinal cord compression,hypercalcemia, pathological and even paralysis, all of which may decrease the quality oflife for cancer patients. Unfortunately, most of the lung carcinoma patients first visitinghave been on latter stages. And30%-40%of them have been bone metastases. Thediagnosis of bone metastases in lung carcinoma patients is very important to judging theclinical stage, determining the treatment and evaluating the survival. Currently, bonemetastasis is diagnosed by CT, MRI, ECT, PET-CT and etc.In accordance with theirvarious principle, they are about the same. But most of them are expensive, bad obedient,and the bone metastasis cannot be found unless it is large enough. It’s the medicalworker’s aim to find a method that is more specific, more sensitive and real time. It is themolecular markers that make it to be possible. The principle is: When the tumour cellmoved to the bone, the tumour cell and various bone cells would secrete multiple cytokines by the interaction between the tumour cell and the bone microenvironment. Itwould lead to bone destruction, tumour cell growth and invasion. Reflected by serum orurine, the cytokines and bone metabolic product in them would be changed. So it ispossible to conjecture the possibility and degree of bone destruction through detectingthe materials above-mentioned in serum or urine. The cytokines and bone metabolicproduct derived from tumour cell and bone cell are variant in specifility and sensitivitywhen they reflect the degree of bone destruction. So it is necessary to research morethorough. And new cytokines are to be explored constantly. It has been explored thatCalcineurin(CaN) was overexpressed in many tumor tissues, we have also found that CaNoverexpresses in SBC-5which has special priority in metastasis to bone, and we identifiedthat CnAαwas significantly overexpressed in small-cell lung cancer tissue with bonemetastasis compared with that without bone metastasis. In the multiple-organ metastasismodel of human SCLC cells, consistent with the formation of bone metastasis by SBC-5cells, the levels of PTHrP in the mouse serum were increased in a time-dependent manner.Previously our study is emphasized at molecular and animal experiment. In this study, wewill to prove the relationship between osteotropism metastasis of LC with CaN and PTHrPby collecting serum of lung cancer patients.Objective: Through examining serum Calcineurin and serum parathyroidhormone-related protein of the patients and judging their difference between patients whohave lung carcinoma with bone metastases and patients without bone metastases.Meanwhile analyse the relationship between serum CaN and PTHrP with biologicalbehaviour of osteotropism metastasis. Explore new molecular markers for early diagnosisand therapeutic evaluation. Methods:1.Collected180cases serum of LC patients whowere all confirmed in pathology or cytology.2.The sample were divided into2groups.One is bone metastases, the other is no bone metastases.3. Choose sex, histological type,pain score, clinical stages and serum ALP, Ca as indicator of biological behaviour ofosteotropism metastasis.4.Detected Calcineurin and serum parathyroid hormone-relatedprotein by ELISA. And analyzed the data by Mann-Whitney U, Kruskal-Wallis H,Wilcoxon and Pearson. Results:1. The CaN and PTHrP in serum of patients with bone metastases are higherthan that in no bone metastases patient（P<0.01）.2. There are significant difference onCaN and PTHrP when patients receive treatment comparing with untreated（P<0.01）.3.It’s not distinct that there are different on CaN and PTHrP in sex pathological patternextent and with or without pain(P>0.05).4. In the layering researc h of patients withoutbone metastases, Either of CaN or PTHrP showed a statistically significant in variousstages(P>0.05).5.There are not association between serum Ca and serum CaN, and sowith PTHrP. There are significant association between serum ALP and serum CaN, and sowith PTHrP. There significant association between serum CaN and serum PTHrP.6. In thebone metastases, there are obvious difference on CaN and PTHrP between effectivepre-therapy and post-treatment and vice versa.Conclusion: The detection of serum CaN and PTHrP may be important indiagnosing and evaluating the effectiveness of treatment in bone metastasis of lungcarcinoma.